Latest News about European Medicines Agency
Recent news which mentions European Medicines Agency
From Benzinga
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
May 02, 2022
From Benzinga
Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
May 02, 2022
Tickers
HZNP
From Benzinga
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
April 25, 2022
From Benzinga
From Benzinga
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
April 22, 2022
From Benzinga
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
April 22, 2022
Tickers
AMYT
From Benzinga
From Benzinga
Europe Approves Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6-11 Years With Type 2 Inflammation
April 07, 2022
From Benzinga
Bristol Myers Squibb Scores Three Back To Back European Approvals For Opdivo In Esophageal, Urothelial Cancer
April 05, 2022
Tickers
BMY
From Benzinga
Immunocore Eye Cancer Cell Therapy Scores European Approval
April 04, 2022
Tickers
IMCR
From Benzinga
From Benzinga
Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD
March 25, 2022
Tickers
NVS
From Benzinga
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer
December 17, 2021
Tickers
MRK
From Benzinga
From Benzinga
Why Are Intercept Pharmaceuticals Shares Falling Today?
December 09, 2021
Tickers
ICPT
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.